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Objective. To determine the most adequate number and size of tissue microarray (TMA) cores for pleomorphic adenoma
immunohistochemical studies.
Study design. Eighty-two pleomorphic adenoma cases were distributed in 3 TMA blocks assembled in triplicate containing
1.0-, 2.0-, and 3.0-mm cores. Immunohistochemical analysis against cytokeratin 7, Ki67, p63, and CD34 were performed and
subsequently evaluated with PixelCount, nuclear, and microvessel software applications.
Results. The 1.0-mm TMA presented lower results than 2.0- and 3.0-mm TMAs versus conventional whole section slides.
Possibly because of an increased amount of stromal tissue, 3.0-mm cores presented a higher microvessel density. Comparing
the results obtained with one, two, and three 2.0-mm cores, there was no difference between triplicate or duplicate TMAs and
a single-core TMA.
Conclusions. Considering the possible loss of cylinders during immunohistochemical reactions, 2.0-mm TMAs in duplicate are
a more reliable approach for pleomorphic adenoma immunohistochemical study. (Oral Surg Oral Med Oral Pathol Oral Radiol
2014;117:81-88)Although tissue microarray (TMA) principles were
originally described by Wan et al. in 1987,1 it was only
after the description of Kononen et al. in 19982 that the
exponential increase in the number of studies using this
laboratory approach was noted. The main advantage of
the TMA method is its ability to aggregate tissue
samples of hundreds of different cases on a single
parafﬁn block, leading to preservation of the original
tissues, laboratory economy, and reduction of execution
time.3-6 On the other hand, limitations that are fre-
quently pointed outdincluding the variable quality of
the tissues used in the TMA, the technical skills
required for arranging and cutting TMA blocks, and,
most relevant, the capacity of TMA to adequately
represent heterogeneous neoplasiasdhave demanded
the development of validation studies.6-8
Therefore, with the purpose of analyzing the usefulness
and reliability of TMA in the immunohistochemical study
of pleomorphic adenoma (PA) of salivary glands, the
authors investigated the expression of cytokeratin 7
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cores assembled in triplicate and compared these to
ﬁndings from conventional whole section slides.MATERIAL AND METHODS
Tissue samples
A total of 82 cases of PA over a 10-year period (January
2001 to December 2011) were retrieved from the
archives of the Oral Diagnosis Department of the Pira-
cicaba Dental School, São Paulo, Brazil, and from
a surgical pathology laboratory in Cascavel, Paraná,
Brazil. The original hematoxylin-eosin stained slides
were reviewed by 3 oral pathologists, and the diagnoses
of all cases were conﬁrmed following the World Health
Organization’s 2005 Histological Typing of Salivary
Gland Tumors guidelines.9TMA construction
Tumor areas were selected and marked on hematoxylin-
eosin-stained sections using an objective marker (NikonStatement of Clinical Relevance
Molecular features of salivary gland tumors remain
to be further investigated, and the use of reliable and
high-throughput laboratory methods such as tissue
microarray may improve the discovery of new
markers related to the clinical behavior of these
neoplasias.
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original parafﬁnblock todetermine the corresponding area
to be used. TMAs were constructed using a manual tissue
arrayer (Sakura Co, Japan) and, depending on the
neoplastic tissue available to be arrayed in each case, 3
representative cylindrical cores of 1.0-, 2.0-, or 3.0-mm
diameter were taken from each tissue block and then
arranged sequentially into a recipient ready-to-use parafﬁn
block (Sakura Co, Japan). The 82 cases of PA were
distributed as follows: 15 cases as whole section conven-
tional slides; 39 on one TMA block containing 1.0-mm
cores; 19 on one TMA block containing 2.0-mm cores;
and 9 on one TMA block containing 3.0-mm cores. Two
cores of normal parotid gland and one of oral squamous
cell carcinoma were inserted in the left upper corner of
each recipient block for orientation. A map specifying the
exact position of each case was prepared to facilitate the
interpretation of the immunohistochemical results.Immunohistochemistry
Brieﬂy, the reactions were conducted in 3-mm sections
of formalin-ﬁxed, parafﬁn-embedded tissues that were
dewaxed with xylene and then hydrated in an ethanol
series. Antigen retrieval was done by immersing the
sections in citrate buffer solution (pH 6.0) for 3 minutes
of pressure cooking, and the endogenous peroxidase
activity was blocked using 10% hydrogen peroxide in 5
baths, each of 5 minutes. After washing in PBS buffer
(pH 7.4), slides were incubated overnight with primary
antibodies anti-cytokeratin 7 (clone OV-TL 12/30,
DakoCytomation, USA, diluted 1:200), anti-p63 (clone
4A4, DakoCytomation, diluted 1:300), anti-Ki67 (clone
MIB1, DakoCytomation, diluted 1:100), and anti-
CD34 (clone QBEnd10, DakoCytomation, diluted
1:50). All slides were subsequently exposed to avidin-
biotin complex and horseradish peroxidase reagents
(LSAB Kit, DakoCytomation) and diaminobenzidine
tetrahydrochloride (DAB, Sigma-Aldrich, St Louis,
MO, USA). Finally, the slides were counterstained with
Carazzi hematoxylin. Positive control sections were
used for each antibody, whereas the negative control
was obtained by omitting the speciﬁc primary antibody.Digital analysis
The immunohistochemical slides were subsequently
scanned into high-resolution images using the Aperio
Scanscope CS Slide Scanner (Aperio Technologies Inc,
Vista, CA, USA). All digital images obtained in .svs
format were visualized with ImageScope software
(Aperio Technologies Inc). Ki67 and p63 nuclear
markers were analyzed using the Nuclear V9 algorithm
(Aperio Technologies Inc) with the following input
parameters: averaging radius, 1; curvature threshold,2.5; lower threshold, 0; upper threshold, 230; minimum
nuclear size, 20; maximum nuclear size, 1,000,000;
minimum roundness, 0.1; minimum compactness, 0;
minimum elongation, 0.1; clear area objective, 240; and
intensity threshold, ranging from 0 to 235. The algo-
rithm PixelCount V9 (Aperio Technologies Inc) was
used for analyzing the cytoplasmic expression of CK7
with the following input parameters: overlap size, 0;
hue value, 1; hue width, 0.5; color saturation threshold,
0.04; and intensity threshold, ranging from 0 to 220.
Microvessel Analysis V1 (Aperio Technologies Inc)
was used for the analysis of CD34 reactivity with the
following input parameters: dark staining threshold,
160; light staining threshold, 210; region joining
parameter, 6; vessel completion parameter, 7; minimum
vessel area threshold, 15; maximum vessel area
threshold, 20,000; maximum vessel wall thickness, 4;
and clear area intensity, 240. The software TMA Lab
(Aperio Technologies Inc) was also used as an auxiliary
tool during the analyses of TMA slides. Cases arranged
in TMAs where at least one core was lost or which did
not present adequate available neoplastic tissue for
analysis were excluded.
With the purpose of determining the amount of
luminal cells (using CK7 staining) and myoepithelial
cells (using p63 staining) in different-sized TMA cores
in relation to the total neoplastic tissue punched, the
results obtained represented the number of positive
luminal and myoepithelial cells in relation to total
tissue, including stromal components. Ki67 analysis
also included neoplastic and stromal cells, whereas
CD34 evaluation comprised the analysis of stromal
vessels in relation to the total tissue area to obtain the
vascular density of each case.Statistical analysis
To compare the immunoexpression of Ki67, p63, CK7,
and CD34 in TMAs containing 1.0-, 2.0-, and 3.0-mm
cores, and in conventional whole section slides, the
Wilcoxon-Mann-Whitney rank sum test was applied,
followed by the Dunn post hoc test when a value of
P  .05 was found. The GraphPad software (version
5.0; GraphPad Software Inc, La Jolla, CA, USA) was
employed for analysis of the data. The current study was
carried out in accordance with the ethical guidelines of
our institution (Process number CEP/FOP 002/2013).RESULTS
Considering the clinical features of the cases included
in the current study, a slight female preponderance was
observed (40 female patients, 35 male, and 7 not
speciﬁed; male-to-female ratio, 0.8:1). The mean age
was 44.4 years, ranging from 10 to 85 years. The
Fig. 1. Immunohistochemical expression of cytokeratin 7 in pleomorphic adenoma using tissue microarray cores of (A) 1.0-mm
diameter (streptavidin-biotin, original magniﬁcation 100), (B) 2.0-mm diameter (streptavidin-biotin, original magniﬁcation 50),
and (C) 3.0-mm diameter (streptavidin-biotin, original magniﬁcation 25) and (D) conventional whole section slides (streptavidin-
biotin, original magniﬁcation 50).
Fig. 2. Immunohistochemical expression of cytokeratin 7 in
pleomorphic adenoma was signiﬁcantly lower in 1.0-mm
tissue microarray cores than in 2.0- and 3.0-mm cores, when
compared with traditional whole section slides (P < .05).
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(34 cases or 41.5%), followed by the palate (14 cases or
17.1%), upper lip (13 cases or 15.9%), and submandibular
gland (10 cases or 12.2%), whereas other intraoral minor
salivary glands were affected in 3 cases (3.7%), and in 8
cases (9.6%) the site was not speciﬁed.
All cases of PA included in the present study presented
ductal structures, beside areas of high and poor cellu-
larity, and most of the cases also showed chondroid
material and hyalinized stroma. Core loss after immu-
nohistochemical reactions was 3%, 5%, and 7% in 1.0-,
2.0-, and 3.0-mm cores, respectively.
The expression pattern of all markers was consistent
with those previously described in the literature and,
aiming to demonstrate the homogeneity in the expres-
sion of all markers in different cases of PA, statistical
analysis was carried out using the immunohistochem-
ical results obtained with conventional whole sec-
tion slides, where no signiﬁcant difference was seen
(P > .05).
CK7 immunostaining was observed in the luminal
cells of ductal structures in all cases evaluated (Figure 1).
The results revealed amean positivity of 0.47, 0.32, 0.50,
and 0.37 for conventional whole section slides and 1.0-
mm, 2.0-mm, and 3.0-mm TMA cores, respectively.
Statistical analysis showed that the CK7 staining index
was signiﬁcantly lower in the 1.0-mm TMA compared
with conventional whole section slides (P < .05),
whereas no signiﬁcant difference was seen between 2.0-and 3.0-mm TMAs in comparison with conventional
whole section slides, even though a slightly lower result
was obtained in 3.0-mm cores (Figure 2).
Similar results were obtained using the myoepithe-
lial marker p63 (Figures 3 and 4) and the proliferative
marker Ki67 (Figures 5 and 6) (mean positivity of
25.9%, 5.7%, 23.3%, and 16% for conventional whole
section slides and 1.0-mm, 2.0-mm, and 3.0-mm TMA
Fig. 4. Signiﬁcantly lower immunohistochemical expression
of p63 was seen in 1.0-mm tissue microarray cores than in
2.0- and 3.0-mm cores, when compared with conventional
whole section slides (P < .05).
Fig. 3. Nuclear immunohistochemical expression of p63 in myoepithelial cells of pleomorphic adenoma using tissue microarray
cores of (A) 1.0-mm diameter, (B) 2.0-mm diameter, and (C) 3.0-mm diameter and (D) conventional whole section slides
(streptavidin-biotin, original magniﬁcation 100).
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positivity of 1.18%, 0.45%, 1.46%, and 0.58% for
conventional whole section slides and 1.0-mm, 2.0-
mm, and 3.0-mm TMA cores, respectively, analyzed
for Ki67), where a signiﬁcantly inferior staining index
was seen with both biomarkers in 1.0-mm TMA
compared with conventional whole section slides (P <
.05), and no signiﬁcant difference was seen whenusing 2.0- and 3.0-mm core TMAs compared with
conventional whole section slides (P > .05). Again, an
inferior result was obtained with 3.0-mm cores than
with 2.0-mm cores.
The vascular antigen CD34 revealed positivity in all
cases analyzed (Figure 7) and, in contrast to the results
observed with the previous markers, the staining pattern
for this stromal marker revealed no signiﬁcant differ-
ence in the vascular density of all TMAs compared with
conventional whole section slides (mean values of 4.55,
3.12, 3.97, and 4.93 for conventional whole section
slides and 1.0-mm, 2.0-mm, and 3.0-mm TMA cores,
respectively) (P > .05), even though an increase could
be seen as the diameter of the cores became larger, with
3.0-mm cores presenting the most similar results to
conventional whole section slides (Figure 8).
Finally, considering that 1.0-mm cores afforded
signiﬁcantly inferior staining indexes for most of the
biomarkers analyzed, and considering that both 2.0- and
3.0-mm cores had similar results to conventional whole
section slides, the use of 2.0-mm TMAs would be
preferred because of the lower damage caused to the
original blocks. Therefore, we subsequently determined
how many 2.0-mm cores would be appropriate to
adequately represent conventional whole section slides
of PA. For that, the values relating to the third core
were excluded; considering only 2 cores, there was no
signiﬁcant difference between the immunoexpression of
all markers and those seen in conventional whole
section slides (P > .05). Similarly, by excluding the
Fig. 5. Ki67 nuclear immunoexpression observed in pleomorphic adenoma using tissue microarray cores of (A) 1.0-mm diameter,
(B) 2.0-mm diameter, and (C) 3.0-mm diameter and (D) conventional whole section slides (streptavidin-biotin, original
magniﬁcation 100).
Fig. 6. Signiﬁcantly lower immunohistochemical expression
of Ki67 was obtained in 1.0-mm tissue microarray cores than
in 2.0- and 3.0-mm cores, when compared with traditional
whole section slides (P < .05).
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analyzing only the ﬁrst core, no signiﬁcant difference
could be seen between 2.0-mm TMA and conventional
whole section slides (P > .05) (Table I).
DISCUSSION
The ability to simultaneously use of a large number
of cases, the standardization of secondary reactions(immunohistochemistry, in situ hybridization, etc),
a signiﬁcantly reduced reagent volume for a given
investigation and experimental handling time,
improving the laboratory workﬂow, represent advan-
tages of the use of TMAs for molecular studies of
parafﬁn-embedded tissues. However, despite these
beneﬁts, TMA has some limitations, including that the
evaluation of a given marker is reduced from the
conventional whole section slide analysis to a few
tissue cores of only 0.6 to 2.0 mm in diameter. This has
led to concerns because of the morphologic and
molecular heterogeneity of human cancers, necessi-
tating the development of validation studies for each
tumor type.6,10,11
As a consequence, validation studies have been pub-
lished showing the signiﬁcant equivalence of TMA cores
with original whole section slides. Boone et al. (2008)12
validated the TMA technique for studying esophageal
squamous cell carcinoma by demonstrating that 0.6-mm
cores arranged in triplicates affords excellent concor-
dance to conventional whole section histologic slides
when analyzing the expression of CK5/6, CK14,
E-cadherin, Ki67, and p53, whereas only 2 cores proved
to be necessary to obtain results concordant with
those observed in whole section slides of cervical
adenocarcinoma.13 TMAs have also been validated in
lung,14 breast,15,16 bladder,17 vulva,18 and endometrial,19
cancers, demonstrating the utility of cores as small as
0.6 and 1.0 mm, in contrast to the signiﬁcant superiority
of 2.0-mm cores observed in the current study, which
Fig. 7. CD34 immunoexpression in pleomorphic adenoma using tissue microarray cores of (A) 1.0-mm diameter (streptavidin-
biotin, original magniﬁcation 100), (B) 2.0-mm diameter (streptavidin-biotin, original magniﬁcation 50), and (C) 3.0-mm
diameter (streptavidin-biotin, original magniﬁcation 25) and (D) conventional whole section slides (streptavidin-biotin, original
magniﬁcation 50).
Fig. 8. Investigating the vascular marker CD34, no signiﬁcant
difference could be seen among tissue microarray cores of
different sizes and conventional whole section slides (P >
.05), although an increased expression of the protein could be
noted in larger tissue microarray cores, revealing that more
stromal component would be available in these tissue
microarrays.
Table I. Mean values for CK7, p63, Ki67, and CD34
when using tissue microarrays arranged in triplicate, in
duplicate, or as a single core
Markers Slide design 3 cores*y 2 cores* 1 corey
Cytokeratin 7 CWSS 0.47 0.47 0.47
1.0-mm 0.32 0.32 0.31
2.0-mm 0.50 0.51 0.51
3.0-mm 0.37 0.37 0.33
p63 (%) CWSS 25.9 25.9 25.9
1.0-mm 5.7 5.2 5.1
2.0-mm 23.3 23.7 23.9
3.0-mm 16 16.4 17.7
Ki67 (%) CWSS 1.18 1.18 1.18
1.0-mm 0.45 0.44 0.38
2.0-mm 1.46 1.38 1.27
3.0-mm 0.58 0.59 0.59
CD34 (vessels/mm2) CWSS 4.55 4.55 4.55
1.0-mm 3.12 3.30 3.03
2.0-mm 3.97 3.96 3.82
3.0-mm 4.93 4.90 5.24
CWSS, conventional whole section slides.
*No signiﬁcant difference was seen in the mean value of the reactions
when comparing all markers arranged as triplicate or duplicate
(P > .05).
yNo signiﬁcant difference was seen in the mean value of the reactions
when comparing all markers arranged as triplicate or as one single
core (P > .05).
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morphic adenomas that would require further neoplastic
tissue in the cylinders so that an adequate comparison
with conventional whole tissue sections could be ob-
tained. Moreover, although studies have been conductedusing TMA in the molecular investigation of salivary
gland tumors,20-22 to date, no attempt has been made to
validate this technique in this group of lesions, and its
usefulness and reliability in the investigation of
OOOO ORIGINAL ARTICLE
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remain debatable.
In the present study, using 4 immunohistochemical
markers with different staining patterns in PA, the
authors observed that TMAs containing cores of 2.0-
and 3.0-mm diameter offered results similar to those
observed in conventional whole section slides, whereas
1.0-mm TMAs showed signiﬁcantly lower results.
Because the preservation of neoplastic tissue is an
important concern, 2.0-mm TMAs would be more
desirable than 3.0-mm cores. Since the analysis of all
markers included both neoplastic and stromal compo-
nents present in conventional whole section slides and
TMA cores, the signiﬁcantly inferior results obtained
with 1.0-mm TMAs could be explained by a technical
inaccuracy during tissue punching, in which undesir-
able stromal tissues would be more frequently inserted
in the TMA block. Similarly, the inferior results
(although not statistically signiﬁcantly) of 3.0-mm
TMAs compared with 2.0-mm TMAs could also
represent a higher amount of stromal component
punched together with neoplastic tissue, which was
diminished when using 2.0-mm cores. The increased
amount of stromal component in 3.0-mm TMAs is
further supported by the increased vascular density seen
with the CD34 reaction compared with that observed in
1.0- and 2.0-mm cores. Hence, the use of larger cores
would be more appropriate circumstances where anal-
ysis of the stromal compartment would be the main
object of study.
In determining how many cores would be adequate
to represent the conventional whole section slides of
PA, we showed that a single 2.0-mm core would
offer results similar to those obtained with conventional
whole section slides. However, because of the frequent
loss of TMA cores after immunohistochemical proce-
dures and the high morphologic heterogeneity of
pleomorphic adenomas, it would be more advisable to
use a second core for each case.
In this study, the authors evaluated the immuno-
staining of CK7 protein, known to be expressed in the
luminal cells of ductal structures of normal and
neoplastic tissues23; CD34, which has been shown to
adequately illustrate the vascular component of PA24;
the nuclear marker p63, which is related to myoepi-
thelial differentiation25; and the proliferative marker
Ki67, which indicates the proliferative potential of the
tumor.20
In conclusion, despite the ﬁnding that one well-
sampled 2.0-mm core could provide results similar to
those of TMAs arranged in duplicate and triplicate, the
authors suggest that, because of the possibility of tissue
loss during additional laboratory procedures, 2.0-mm
TMAs assembled in duplicate are a more desirable
arrangement, representing a reliable, cost-effective, andhigh-throughput method for immunohistochemical
study of PA.REFERENCES
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